- Home
- AMGN vs UBER Comparison
AMGN vs UBER Comparison
Compare AMGN & UBER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- UBER
- Stock Information
- Founded
- AMGN 1980
- UBER 2009
- Country
- AMGN United States
- UBER United States
- Employees
- AMGN N/A
- UBER N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- UBER Business Services
- Sector
- AMGN Health Care
- UBER Consumer Discretionary
- Exchange
- AMGN Nasdaq
- UBER Nasdaq
- Market Cap
- AMGN 141.6B
- UBER 126.2B
- IPO Year
- AMGN N/A
- UBER 2019
- Fundamental
- Price
- AMGN $272.11
- UBER $67.33
- Analyst Decision
- AMGN Buy
- UBER Strong Buy
- Analyst Count
- AMGN 22
- UBER 35
- Target Price
- AMGN $324.05
- UBER $91.67
- AVG Volume (30 Days)
- AMGN 3.5M
- UBER 24.5M
- Earning Date
- AMGN 02-04-2025
- UBER 02-05-2025
- Dividend Yield
- AMGN 3.50%
- UBER N/A
- EPS Growth
- AMGN N/A
- UBER 307.30
- EPS
- AMGN 7.83
- UBER 2.02
- Revenue
- AMGN $32,534,000,000.00
- UBER $41,955,000,000.00
- Revenue This Year
- AMGN $20.07
- UBER $19.77
- Revenue Next Year
- AMGN $3.59
- UBER $15.58
- P/E Ratio
- AMGN $34.74
- UBER $33.35
- Revenue Growth
- AMGN 21.25
- UBER 16.70
- 52 Week Low
- AMGN $253.30
- UBER $54.84
- 52 Week High
- AMGN $346.85
- UBER $87.00
- Technical
- Relative Strength Index (RSI)
- AMGN 54.19
- UBER 56.59
- Support Level
- AMGN $267.15
- UBER $64.62
- Resistance Level
- AMGN $272.82
- UBER $69.58
- Average True Range (ATR)
- AMGN 4.68
- UBER 1.85
- MACD
- AMGN 2.37
- UBER 0.85
- Stochastic Oscillator
- AMGN 75.60
- UBER 76.46
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About UBER Uber Technologies Inc.
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides "aerial ride-sharing." Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 150 million users who order rides or food at least once a month.